TABLE 5.
RECOMMENDED AREAS FOR FUTURE SCP RESEARCH AND METHODOLOGICAL CONCERNS TO BE ADDRESSED
Content |
|
1. When do survivors and providers prefer for SCP to be delivered? |
2. How frequently do survivors and providers prefer for SCP to be delivered? |
3. Which type of provider most effectively develops SCP? |
4. Which type of provider most effectively delivers SCP? |
|
Dissemination and implementation |
|
1. What determines whether survivors and primary care providers receive and retain SCP? |
2. Does a limited-content SCP template minimize resources required for SCP use? |
3. Does a limited-content SCP template increase SCP use? |
|
Outcomes |
|
1. What are the “active ingredients” of effective transitions from treatment to follow-up care? |
2. Are survivors who receive SCP more likely than survivors without SCP to get guideline-concordant care? |
3. Are survivors who receive SCP less likely than survivors without SCP to receive duplicative services? |
4. How confident are providers in managing survivors’ follow-up care? |
5. What costs are associated with SCP use. |
6. Which patient-, provider-, and cancer program-level variables are most relevant SCP-related outcomes? |
|
Methodological concerns to be addressed |
|
1. Biases associated with observational studies may be addressed by using RCT. |
2. Inability to infer causality may be addressed with longitudinal studies. |
3. Limited generalizability may be addressed with more diverse samples of cancer programs, providers, and survivors that reflect the diversity found in practice. |
4. Concerns about validity and reliability may be addressed through systematic testing of data collection tools. |
Abbreviations for all tables: ASCO, American Society of Clinical Oncology; BCS, breast cancer survivor; CCS, colorectal cancer survivor; IOM, Institute of Medicine; NCI, National Cancer Institute; PCP, primary care provider; RCT, randomized controlled trial; SCP, survivorship care plan; TS, treatment summary